The first stock of AI Drug Delivery, Gene Targeting Technology (07666), surged on its first day, with capital flocking to the biotechnology sector.

On May 13th, medication technology (07666) "the first global AI drug delivery stock" officially rang the bell, officially listed on the main board of the Hong Kong Stock Exchange, marking a new stage in the AI pharmaceutical race from "small molecule discovery" to "large molecule delivery". On the first day of listing, medication technology was highly sought after by the capital market, with strong stock performance. The stock price opened at 173.14%, reaching HK$28.68, with the trading volume quickly exceeding HK$1.2 billion, reflecting the market's optimism towards the "AI+ biologic large molecule" track. During the IPO period, medication technology received overwhelming response, with the public offering in Hong Kong oversubscribed by over 6900 times, locking in funds exceeding HK$73 billion, setting a new record for medical health IPO oversubscription in Hong Kong and becoming the new "frozen capital king" of Hong Kong IPOs this year. Furthermore, the international placement also achieved impressive results, attracting over 280 institutional investors and oversubscribed by 82 times. Notably, the company's cornerstone investors list includes global giants like BlackRock leading international asset management giants, as well as top international financial institutions like UBS, Future Fund, and specialized medical funds like Hillhouse, Deerfield, RTW, and Clearpool. International tech funds like Warburg Pincus and IDG, as well as Chinese major public funds like CICC, ICBC, Hua Xia, Rich Fund, and GF Fund, are also standing together. During the bell ringing ceremony, the management of medication technology expressed their grand vision for the company's future. The co-founder, chairman, and CEO, Dr. Lai Caida, pointed out that the future of biomedicine is no longer just about "taking medicine when ill," but medication technology's ambition is to use AI to create nano rockets, achieve precise navigation in the intra-space of the human body's 300 trillion cells, writing the codes of nucleic acids and proteins into cells, reprogramming disease cells and aging cells into healthy cells. Medication technology's leading position in the field is attributed to its unique and advanced "AI for Nano" technology. As a global leader in AI-driven pharmaceutical nanomaterial solutions, the company has independently developed the world's first AI nano delivery platform, NanoForge. This platform integrates the world's largest million-level LNP lipid library and relies on its innovative nanomaterial AI-based model and the industry's first nano delivery AI system ALAN, achieving an end-to-end closed loop from molecular generation, property prediction to dry-wet experiments. With this engine, medication technology has achieved a breakthrough in the precise targeted delivery of eight key organs or tissues in human body, surpassing traditional LNP companies that are mostly limited to the liver. By deeply integrating AI with nanomaterials, the company is accelerating the reshaping of the value chain of large molecule drugs. Medication technology plans to continuously invest the funds raised in this IPO into AI infrastructure construction, core technology research and development, global pipeline clinical progression, and expanding AI nano delivery technology to anti-aging, animal health, and broader life science fields. The successful listing of medication technology not only brings a rare AI pharmaceutical target with underlying platform technology output capability to the Hong Kong stock market, but also marks China's biomedicine underlying technology advancing to the forefront globally. With the paradigm shift in innovative drug development logic from the "target era" to the "delivery era," the delivery method has become a key factor in changing the fate of molecules and determining drug efficacy. Standing at this new starting point on the Hong Kong Stock Exchange, medication technology will continue to build a new research and development paradigm of "rocket + satellite" through the dual-drive mode of "AI + nano delivery," bringing more precise and efficient innovative therapies to global patients and opening up the vast universe of AI pharmaceuticals.